We found that the cytosolic but not the nuclear expression of ER β was associated with better OS in LAC tumors but not associated with EGFR mutation. PC9 (EGFR exon 19 deletion mutant Gefitinib-vulnerable cells) and A549 (EGFR wild type Gefitinib-resistant cells) cancer cells were used to evaluate the in vitro therapeutic benefits of combining Gefitinib and Tamoxifen. We assessed the association between EGFR mutations as well as ER α/ β expression/location and overall survival in a cohort of 55 patients with LAC from a single hospital. We evaluated the relationship between the two receptors and the potential therapeutic benefit with Gefitinib and Tamoxifen. Some studies have shown that activation of estrogen and estrogen receptor α or β (ER α/ β) promote adenocarcinoma. Epidermal growth factor receptor (EGFR) mutations are known as oncogene driver mutations and with EGFR mutations exhibit good response to the EGFR tyrosine kinase inhibitor Gefitinib.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |